Abalone Bio is an Emeryville-based preclinical biotech building target-activating antibodies for diseases other drugs can't reach. Its FAST platform pairs engineered yeast cells with AI/ML to screen ~100 million antibodies per experiment for functional activity, not just binding, with an initial focus on G-protein coupled receptors (GPCRs) and metabolic disease.
Max Cao is the co-founder and CEO of Jacobi Robotics, an Emeryville, California startup building AI-first software that programs industrial robot arms up to 20x faster. A mechanical engineer trained at Imperial College London and UC Berkeley's BAIR Lab under Ken Goldberg, and a former McKinsey consultant, Cao left academia to attack a problem most people never see: the way robots are programmed has barely changed since the 1980s. Jacobi's motion-planning technology cuts deployment from a month to under a day, claims 1000x less compute, and handles the singularities that freeze robot arms mid-task. The company launched publicly in July 2024 with a $5M seed round led by Moxxie Ventures.
Shawn Manchester is the CEO of Triplebar, an Emeryville-and-Oakland based biotech building generative AI 'genome language models' paired with ultra-high-throughput phenotypic screening to slash the cost of biologic therapeutics and food proteins. A chemical engineer by training (BS Brown, PhD MIT), he was the lead scientist in the first AI-versus-human strain engineering contest at Zymergen before joining Triplebar in 2021, where he rose from VP of Product to COO to CEO in March 2025.
Michael Harrington is the Chief Executive Officer, Practice Management at Vituity, the physician-owned, multispecialty partnership headquartered in Emeryville, California. An accountant by training, he has spent more than three decades inside healthcare operations and stepped into the CEO role in 2002 after years as Vituity's CFO.
Babylist is the operating system for new parenthood — a universal baby registry that grew into an ecommerce destination, a content engine, a healthcare brand, and now a chain of experiential showrooms. Founded in 2011 by ex-Amazon engineer Natalie Gordon, the company hit $750M in 2025 revenue while staying founder-led, profitable, and unapologetically focused on the parent.
Cheng Liu is the founder, President, and CEO of Eureka Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Emeryville, California. A molecular cell biologist trained at UC Berkeley and Peking University, Liu invented a novel class of TCR mimic antibodies that allow engineered T cells to recognize intracellular tumor antigens - a major challenge in treating solid tumors. Since founding Eureka in 2006 after a decade at Chiron/Novartis, he has built a pipeline of ARTEMIS T-cell therapies targeting liver cancer, multiple myeloma, and neuroblastoma, with the company's ECT204 program earning FDA RMAT Designation in January 2026 - one of the highest-priority designations the FDA gives to regenerative medicine therapies. Eureka has raised over $168 million in total funding and holds more than 500 patents worldwide.
Ryan Spencer is the CEO of Dynavax Technologies, the Emeryville biotech behind HEPLISAV-B and the CpG 1018 adjuvant. He joined as an interim controller in 2005, climbed for fourteen years through finance, IR, and commercial roles, and took the top job in December 2019. Under him, Dynavax supplied adjuvant for nearly a billion COVID-19 vaccine doses and, in December 2025, agreed to be acquired by Sanofi for roughly $2.2 billion.